Health and Healthcare
Lexicon New Alzheimer's Disease Trial Dosing (LXRX)
Published:
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has announced that dosing has commenced in its Phase IIa clinical trial with LX6171. This is an oral drug candidate that is implied for the treatment of cognitive impairment disorders such as Alzheimer’s disease, schizophrenia, and vascular dementia.
The initial stage of the trial will assess the bioavailability of a new oral-suspension formulation in healthy elderly subjects with a second stage evaluating safety, tolerability and cognitive effects in elderly subjects with age-associated memory impairment.
This was issued ahead of its R&D webcast at Noon EST today. Shares have not traded in pre-market trading and closed at $3.20 yesterday; its 52-week trading range is $2.80 to $4.40.
Jon C. Ogg
December 5, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
